Altimmune (ALT) Stock
Altimmune (ALT) closed at $1.56 on Nov 16, 2026; its Tenet Score is 54 of 100 against 409 Healthcare peers.
Key stats
- Previous close
- $1.56
- Nov 16, 2026
- Market cap
- $303.6M
- share price × the latest quarter's diluted weighted-average share count (vendor)
- Dividend yield
- 0.00%
- reinvests all
- 52-week range
- 1.58 – 6.44
- low → high
- Tenet Score
- 54/100
- Mixed · 409 Healthcare peers
Industry: Drugs · see every company filed here →
Altimmune Inc scores 54/100. Mixed. Strongest on value and financial health, growth is the soft spot versus 409 Healthcare peers.
Tenet Score · vs sector
n=409Factor grades
Price
The whole report, at a glance · every card is a live peek, click any to open the section
- ✕ Buffett Quality
- ✕ Piotroski F-Score
- ✕ Graham Defensive
- ✕ Quality Compounder
- ✕ Drawdown Context
- ~ Reversal Evidence
Pays 0.00%. Yield is one component of total return.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agon…
Similar-sized companies in Drugs
The 10 companies in this industry closest in market cap, as of Nov 13, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| Pacific Biosciences of California, IncPACB | 40 | $613.3M |
| Climb Bio Inc.CLYM | 62 | $608.5M |
| Sana Biotechnology IncSANA | 34 | $605.3M |
| Evotec SEEVO | 51 | $561.8M |
| Capricor Therapeutics IncCAPR | 51 | $554.1M |
| Phathom Pharmaceuticals, Inc.PHAT | 33 | $492.6M |
| Candel Therapeutics IncCADL | 45 | $486.4M |
| Avalo Therapeutics IncAVTX | 56 | $448.7M |
| Cerus CorpCERS | 33 | $400.9M |
| Editas Medicine, Inc.EDIT | 27 | $334.9M |
Common questions
What sector and industry is Altimmune in?
Altimmune is in the Healthcare sector and the Drugs industry.
What is Altimmune's Tenet Score?
Altimmune's Tenet Score is 54 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.




